• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

India Globalization Capital Appoints Carrolee Barlow, MD, PhD as Advisor

March 12, 2018



BETHESDA, Md., March 12, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE:IGC) today announces that Carrolee Barlow, MD, PhD has been appointed to the Company as an Advisor to help develop solutions and treatments for Parkinson’s disease utilizing cannabis related formulations. Dr. Barlow is a renowned expert in neuroscience & neurodegeneration and is currently the CEO of the Parkinson’s Institute and Clinical Center.


Dr. Barlow’s illustrious career has focused on clinical care, laboratory and clinical research, academia and industry. She is the founder and former Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc. in San Diego, California, a biotechnology company focused on the discovery and development of small molecules that stimulate adult hippocampal neurogenesis for the treatment of neurological and psychiatric disease using human neural stem cell technology. Prior to BrainCells, Dr. Barlow was a professor at Salk Institute for Biological Studies, running a lab that used animal models to study neuro-diseases and eventually helping to establish the field of neurogenomics. After that she supervised neuroscience biology, global exploratory, licensing and full phase efforts as the Director of Molecular Neuroscience and the Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories. Moreover, she serves as an advisory board member for several biotechnology companies and disease foundations.


Dr. Barlow received her MD from the University of Utah and did her residency in Internal Medicine at The New York Hospital, Cornell Medical Center. She went on to obtain a PhD in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. Shortly thereafter, she joined the National Institutes of Health and completed medical sub-specialty training in the field of endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute.


Dr. Barlow’s goal is to find solutions and treatments for Parkinson’s disease in the same way she has done with other diseases. Working with the FDA and others, she is finding ways to transform clinical studies for neurodegenerative diseases by evaluating the science and designing studies in a way that turns research into new treatments.


“We believe that cannabis-based compounds can become part of the solution to treat the symptoms of challenging and progressive medical conditions such as Parkinson’s disease and movement disorders. Dr. Barlow is highly respected in the field and we look forward to working together to bring cannabis-based options to those afflicted by this difficult diagnosis,” stated Ram Mukunda, CEO of IGC.


About IGC:


IGC has two lines of business, a legacy infrastructure and commodity trading business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). The Company is based in Maryland, USA.


For more information please visit www.igcinc.us; www.igcpharma.com; www.hyalolex.com


Follow us on Twitter @IGCIR and Facebook.com/IGCIR/


Forward-looking Statements


Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.





Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.